Oral versus vaginal misoprostol for medical management of early foetal demise

ISRCTN ISRCTN85124072
DOI https://doi.org/10.1186/ISRCTN85124072
Secondary identifying numbers N/A
Submission date
26/02/2009
Registration date
21/04/2009
Last edited
24/10/2019
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Pregnancy and Childbirth
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Dr Elaine Gouk
Scientific

University Hospital of North Tees
Hardwick Road
Stockton-on-Tees, Cleveland
TS19 8PE
United Kingdom

Study information

Study designRandomised controlled trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Hospital
Study typeTreatment
Participant information sheet No participant information sheet available
Scientific titleA randomised controlled trial of oral versus vaginal misoprostol for medical management of early foetal demise
Study objectivesWhen used in conjunction with oral mifepristone (200 mg), a single dose of vaginal misoprostol (800 micrograms) has a higher success rate in treating early foetal demise than an oral regimen of misoprostol (600/400/400 micrograms).
Ethics approval(s)South Tees Hospital Trust Ethics Committee, 23/09/1997, ref: 97/69
Health condition(s) or problem(s) studiedMedical management of miscarriage
InterventionIn both groups, oral mifeprostone (200 mg) was given and then the misoprotol administered 48 hours later. The vaginal regimen was given once only. If no products were passed/seen, even on vaginal speculum examination, this could be repeated the next day. The oral regime (600/400/400 micrograms) was given at two hourly intervals. Again, if the miscarriage had not completed, this could be reviewed the next day.
Intervention typeDrug
Pharmaceutical study type(s)
PhaseNot Specified
Drug / device / biological / vaccine name(s)Mifepristone, misoprostol
Primary outcome measureClinically diagnosed completion of miscarriage
Secondary outcome measures1. Parity, assessed at initial presentation
2. Anembryonic/embryonic early foetal demise assessed at time of ultrasound scan and miscarriage diagnosis
3. Side effects (pain, diarrhoea, vomiting), assessed during treatment and inpatient stay
4. Analgesia use
Overall study start date01/01/1997
Completion date30/12/2000

Eligibility

Participant type(s)Patient
Age groupAdult
SexFemale
Target number of participants240
Key inclusion criteriaWomen with an ultrasound diagnosis of (singleton) early foetal demise, with no medical contraindications or known allergy to misoprostol or mifepristone.
Key exclusion criteria1. Heavy smokers (of >20 cigarettes day)
2. Aged >35 years
3. Severe asthma
4. Cardiovascular disease, hypertension (blood pressure [BP] >160/100 mmHg)
5. Chronic adrenal, renal or hepatic failure
6. Porphyria or haemorrhagic disorders
7. Long term corticosteroid
8. Anticoagulant or non-steroidal anti-inflammatory drug (NSAID) therapy
9. Known allergy to mifepristone or misoprostol
Date of first enrolment01/01/1997
Date of final enrolment30/12/2000

Locations

Countries of recruitment

  • England
  • United Kingdom

Study participating centre

University Hospital of North Tees
Stockton-on-Tees, Cleveland
TS19 8PE
United Kingdom

Sponsor information

South Tees Hospitals NHS Trust (UK)
Hospital/treatment centre

The James Cook University Hospital
Marton Road
Middlesbrough
TS4 3BW
England
United Kingdom

Website http://www.southtees.nhs.uk/live/
ROR logo "ROR" https://ror.org/02js17r36

Funders

Funder type

Hospital/treatment centre

The James Cook University Hospital (UK)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article results 01/10/2009 24/10/2019 Yes No

Editorial Notes

24/10/2019: Publication reference added.
09/09/2016: No publications found in PubMed, verifying study status with principal investigator.